JP7792920B2 - ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 - Google Patents

ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法

Info

Publication number
JP7792920B2
JP7792920B2 JP2022581465A JP2022581465A JP7792920B2 JP 7792920 B2 JP7792920 B2 JP 7792920B2 JP 2022581465 A JP2022581465 A JP 2022581465A JP 2022581465 A JP2022581465 A JP 2022581465A JP 7792920 B2 JP7792920 B2 JP 7792920B2
Authority
JP
Japan
Prior art keywords
compound
formula
free base
composition
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022581465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532330A (ja
JP2023532330A5 (https=
Inventor
ニール バックリー，
ダン ベルモント，
サラ ベトゥーン，
クリスタ ディアス，
ブライアン ハウザー，
ミョン ク キム，
クマール カナン，
Original Assignee
インブリア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インブリア ファーマシューティカルズ， インコーポレイテッド filed Critical インブリア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023532330A publication Critical patent/JP2023532330A/ja
Publication of JP2023532330A5 publication Critical patent/JP2023532330A5/ja
Priority to JP2025195295A priority Critical patent/JP2026027462A/ja
Application granted granted Critical
Publication of JP7792920B2 publication Critical patent/JP7792920B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2022581465A 2020-06-30 2021-06-28 ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法 Active JP7792920B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025195295A JP2026027462A (ja) 2020-06-30 2025-11-14 ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046123P 2020-06-30 2020-06-30
US202063046120P 2020-06-30 2020-06-30
US63/046,120 2020-06-30
US63/046,123 2020-06-30
PCT/US2021/039305 WO2022005928A1 (en) 2020-06-30 2021-06-28 Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025195295A Division JP2026027462A (ja) 2020-06-30 2025-11-14 ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法

Publications (3)

Publication Number Publication Date
JP2023532330A JP2023532330A (ja) 2023-07-27
JP2023532330A5 JP2023532330A5 (https=) 2024-06-21
JP7792920B2 true JP7792920B2 (ja) 2025-12-26

Family

ID=79314883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022581465A Active JP7792920B2 (ja) 2020-06-30 2021-06-28 ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法
JP2025195295A Pending JP2026027462A (ja) 2020-06-30 2025-11-14 ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025195295A Pending JP2026027462A (ja) 2020-06-30 2025-11-14 ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法

Country Status (8)

Country Link
EP (1) EP4171233A4 (https=)
JP (2) JP7792920B2 (https=)
KR (1) KR20230031320A (https=)
CN (1) CN116056711B (https=)
AU (1) AU2021299266A1 (https=)
CA (1) CA3188286A1 (https=)
IL (1) IL299547A (https=)
WO (1) WO2022005928A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235297A1 (en) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Compounds and methods for increasing efficiency of cardiac metabolism

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216936A1 (en) 2017-06-20 2019-07-18 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) * 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102850296B (zh) * 2012-09-29 2015-01-07 瑞阳制药有限公司 曲美他嗪的制备方法
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation
EP3976101A4 (en) * 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216936A1 (en) 2017-06-20 2019-07-18 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism

Also Published As

Publication number Publication date
JP2026027462A (ja) 2026-02-18
JP2023532330A (ja) 2023-07-27
WO2022005928A1 (en) 2022-01-06
AU2021299266A1 (en) 2023-02-02
IL299547A (en) 2023-02-01
CN116056711B (zh) 2026-03-31
EP4171233A1 (en) 2023-05-03
CN116056711A (zh) 2023-05-02
KR20230031320A (ko) 2023-03-07
CA3188286A1 (en) 2022-01-06
EP4171233A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
JP7174132B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
TWI804933B (zh) 用作cdk7激酶抑制劑的化合物及其應用
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
US20250074878A1 (en) Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
JP2026027462A (ja) ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法
TW201200511A (en) Crystalline salts of a potent HCV inhibitor
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
TW202328084A (zh) 聯芳基ｙａｐ／ｔａｚ—ｔｅａｄ蛋白—蛋白相互作用抑制劑之結晶形式
JP2018518515A (ja) フェニルアミノピリミジン化合物またはその塩の多形物
TWI907075B (zh) 一種嘧啶苯胺類化合物的晶型、製備方法及應用
JP2026506400A (ja) デルゴシチニブの固体形態及びその方法
WO2026095022A1 (ja) キノリン置換化合物の結晶
WO2026040323A1 (zh) 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用
JP2025527820A (ja) キノリン誘導体阻害剤の結晶形、及びその調製方法並びに用途
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251216

R150 Certificate of patent or registration of utility model

Ref document number: 7792920

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150